Skip to main content
Clinical Trials/NCT03683654
NCT03683654CompletedNot Applicable

Mining the Urinary and Serum Metabolome for Discovery of Novel Biomarkers of Dietary Exposure in the EPIC Calibration Study

International Agency for Research on Cancer0 sites494 target enrollmentStarted: April 26, 2012Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Sponsor
Enrollment
494
Primary Endpoint
Metabolite concentrations in plasma and urine

Study Overview

Brief Summary

This proposal aims at identifying new biomarkers of dietary exposure using metabolomic approaches. This project is based on the European Prospective Investigation on Cancer and Nutrition (EPIC) Calibration Study and more particularly upon a subset of 494 men and women from 4 European countries (Germany, Greece, Italy and France). Urine and blood samples are analyzed by untargeted metabolomics.

Detailed Description

Subjects participating in the study are characterized by the availability of one 24-hr urine sample, blood serum, 24-hr dietary recall (24HDR) and food frequency questionnaire (FFQ) data.

The main objectives of the proposal are:

  1. To collect a set of high-quality metabolomic data containing rich information on the food-derived metabolome.
  2. To mine this data in different Metabolome-Wide Association Studies in order to identify food-derived metabolites discriminating consumers and non-consumers of various foods, nutrients and dietary patterns.
  3. To identify the food-derived metabolites characteristic of the consumption of the different foods/nutrients and dietary patterns.

Study Design

Study Type
Observational
Observational Model
Cohort
Time Perspective
Cross Sectional

Eligibility Criteria

Ages
30 Years to 70 Years (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Metabolite concentrations in plasma and urine

Time Frame: 1 day

Food-derived Metabolite concentrations in plasma and urine are measured by high resolution mass spectrometry coupled to ultrahigh performance chromatography.

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor
International Agency for Research on Cancer
Sponsor Class
Other
Responsible Party
Sponsor

Similar Trials